Linezolid Kabi

Linezolid, the active ingredient in Linezolid Kabi, is an oxazolidinone presented as an intravenous solution for intravenous use. It is indicated for the treatment of serious bacterial infections, such as complicated skin and soft‑tissue infections, community‑acquired and nosocomial pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) or vancomycin‑resistant Enterococcus (VRE), primarily in hospitalized patients.

GNH USA supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is an oxazolidinone antibacterial used to treat infections caused by Gram‑positive bacteria.

- Complicated skin and soft tissue infections: effective against MRSA and other resistant organisms, helping resolve infection. - Community‑acquired and nosocomial pneumonia: provides coverage for typical and atypical pathogens, improving respiratory outcomes. - Infections caused by methicillin‑resistant Staphylococcus aureus (MRSA): eradicates MRSA strains resistant to other agents. - Infections caused by vancomycin‑resistant Enterococcus (VRE): offers an alternative treatment option for VRE infections.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Thrombocytopenia: reduction in platelet count, usually reversible.

Serious or Rare Side Effects: - Myelosuppression: severe decrease in blood cell production, may require monitoring. - Peripheral neuropathy: nerve damage presenting as tingling or numbness. - Lactic acidosis: rare metabolic disturbance that can be life‑threatening.

When prescribing Linezolid, several safety considerations should be observed.

- Hematologic monitoring: check complete blood count regularly due to risk of thrombocytopenia and anemia. - Renal and hepatic function: assess baseline and periodic labs as impairment may affect drug handling. - Serotonergic agents: avoid concomitant use with MAO inhibitors or SSRIs because of risk of serotonin syndrome. - Duration of therapy: limit to recommended course length to reduce risk of myelosuppression. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, and retain in original packaging.

Linezolid can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may precipitate serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: increased risk of serotonin toxicity. - Rifampicin: may reduce linezolid plasma concentrations, compromising effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring. - Ethanol: potential for disulfiram‑like reaction causing flushing and nausea. - Anticonvulsants (e.g., carbamazepine): may lower linezolid levels, necessitating therapeutic monitoring.